Alexion Pharmaceuticals Inc. said its non-GAAP net income for the fourth quarter amounted to $1.48 per share, compared with the S&P Capital IQ normalized EPS consensus estimate of $1.27 per share.
EPS rose 17.5% year over year from $1.26.
Aggregate non-GAAP net income totaled $337.6 million, a gain of 17.3% from $287.7 million in the year-earlier period.
Total revenues increased 9.5% on an annual basis to $909.7 million from $830.8 million for the 2016 fourth quarter.
GAAP net income fell year over year to $30 million, or 13 cents per share, from $92.8 million, or 41 cents per share, in the corresponding quarter of 2016.
GAAP earnings were negatively impacted by a $45.8 million charge related to the recently passed U.S. tax reform.
Full-year results
For full-year 2017, the company's non-GAAP net income totaled $5.86 per share, compared with the S&P Capital IQ consensus normalized EPS estimate of $5.66.
EPS rose from $4.62 in 2016.
Aggregate non-GAAP net income totaled $1.34 billion, up from $1.05 billion in 2016.
Full-year 2017 total revenues rose 15.1% year over year to $3.55 billion.
On a GAAP basis, full-year 2017 profit was up to $443.3 million, or $1.97 per share, from $399.4 million, or $1.76 per share, in 2016.
2018 financial guidance
The biotech giant will target revenues in the range of $3.85 billion to $3.95 billion during 2018.
The New Haven, Conn.-based company expects its non-GAAP EPS to be between $6.60 and $6.80, while GAAP EPS is expected in the range of $4.35 to $4.75.
The S&P Capital IQ normalized EPS consensus estimate for 2018 is $7.03.
